About Tessa Therapeutics
Tessa Therapeutics is a clinical-stage immunotherapy company focused on the development of autologous and off-the-shelf, allogeneic therapies for cancer patients.
Our Virus-Specific T cell (VST) platform harnesses the body’s potent anti-viral immune response and has shown compelling results in the treatment of solid tumors.
We are building a portfolio of innovative, next-generation therapies which combine the qualities of VSTs with other immuno-oncology technologies.
Our robust operational and supply chain capabilities enable us to successfully deliver T cell therapy treatments to a large patient pool worldwide. Together with our academic, clinical, and commercial research partners, we have created a fully-integrated approach to the treatment of cancer with immunotherapy.
The immunosuppressive tumor microenvironment presents significant obstacles to the treatment of solid tumors with immunotherapy. Our Virus-Specific T cell (VST) technology overcomes these barriers and has shown promising clinical success.
We have a rapidly growing pipeline of autologous and allogenic therapies targeting multiple cancer indications. These innovative, next-generation therapies combine the qualities of VSTs with other immuno-oncology technologies.
We are committed to working towards a vision of a world without untreatable cancers. We are constantly advancing our understanding of the body’s immune system to design next-generation VST therapies which demonstrate persistence, durability, and tumor penetration with minimal side effects for patients.
Tessa on Twitter
Tessa’s CSO, Dr John Connolly ( @hotirishmonkey), speaks to @parkerici's Jeffrey Bluestone ( @kickassscience1) about the impact of cell #immunotherapy in changing the field of pharmaceutical drug development. Watch the interview: https://t.co/Zc2Vi86jqN #celltherapy #solvecancer https://t.co/NCEnHkpurF
Tessa Therapeutics, in collaboration with @bcmhouston, today presented preclinical results showing enhanced T cell responses against HER2-positive solid tumors using a novel combination CAR T cell therapy, at @ASGCTherapy’s #ASGCT19. More details here: https://t.co/waXQICXMkg https://t.co/amar8vXJOw
Tessa’s Media Channel
CNBC Anchor, Nancy Hungerford speaks with Tessa’s CFO, Desmond Lim about the Company’s future plans and the promise of Virus-Specific T Cell (VST) cancer immunotherapy.